AlzeCure Pharma AB (publ) (ALZCUR.ST) Research

AlzeCure Pharma AB (publ) is a pharmaceutical firm focused on pioneering drug treatments for debilitating conditions impacting the central nervous system (CNS). The company's pipeline of potential medicines is rooted in three distinct research platforms: NeuroRestore, Alzstatin, and Painless. Among its experimental compounds, ACD856 is currently in Phase I clinical trials for multiple indications, including Alzheimer's disease, sleep disturbances, traumatic brain injuries, and Parkinson's disease. Furthermore, ACD857, ACD679, and ACD680 are being developed for Alzheimer's treatment. Another candidate, ACD440, a TRPV1 antagonist intended for neuropathic pain, has successfully completed its Phase I clinical assessment. Additionally, TrkA-NAM is in development to alleviate osteoarthritic pain. Founded in 2012, AlzeCure Pharma AB (publ) maintains its headquarters in Huddinge, Sweden.

Market snapshot

Symbol
ALZCUR.ST
Price
$3.77
Day change
+2.17%
Market cap
$494.9M
P/E ratio
-7.10x
52-week range
1.15542-5.68958
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months

Peer companies

  • AcuCort AB (ACUC.ST)
  • Boule Diagnostics AB (publ) (BOUL.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
  • Karolinska Development AB (publ) (KDEV.ST)
  • Klaria Pharma Holding AB (publ.) (KLAR.ST)
  • Lipum AB (publ) (LIPUM.ST)
  • Mentice AB (publ) (MNTC.ST)

Open AlzeCure Pharma AB (publ) (ALZCUR.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.